Findings

What do systematic reviews say?

11 questions · 11 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 4 · 36.4%Very low 0 · 0%Low 6 · 54.5%Moderate 1 · 9.1%High 0 · 0%

Oral gabapentin vs placebo

Acquiring ability to walk · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Low

Oral gabapentin vs placebo

Change in quality of life · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Low

Oral gabapentin vs placebo

Change in pulmonary function · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 65 participants
Low

Oral gabapentin vs placebo

Time from beginning of treatment until death or full‐time ventilation · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 84 participants
Moderate

Oral gabapentin vs placebo

Adverse events related to treatment · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 65 participants
Low

Oral gabapentin vs placebo

Change in disability score · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Low

Oral gabapentin vs placebo

Muscle strength · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Low

Oral gabapentin vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…

1 finding from 1 review

Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes
12 weeks
Four of the participants withdrew from the study by Kimos et al 2007 due to adverse effects, but neither the type of adverse effect nor the trial group was specified.
1 study · 44 participants
GRADE not reported

Oral gabapentin vs placebo

Participants' assessment of global function (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…

Oral gabapentin (anticonvulsant) showed no clear difference in participants' assessment of global function (VAS) compared with placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes
12 weeks
MD -1.50 [-3.10, 0.10]
1 study · 44 participants
GRADE not reported

Number of tender sites on muscles of mastication (palpation index) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…

Oral gabapentin (anticonvulsant) led to lower number of tender sites on muscles of mastication (palpation index) compared with placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes
12 weeks
MD -4.56 [-6.99, -2.13]
1 study · 44 participants
GRADE not reported

Oral gabapentin vs placebo

Spontaneous pain in the TMJ (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…

Oral gabapentin (anticonvulsant) led to lower spontaneous pain in the TMJ (VAS) compared with placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes
12 weeks
MD -3.20 [-4.71, -1.69]
1 study · 44 participants
GRADE not reported